{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:29:15Z","timestamp":1794036555175,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Healthcare Quality Improvement Partnership","id":[{"id":"https:\/\/ror.org\/04qj6xg77","id-type":"ROR","asserted-by":"crossref"}]},{"name":"IIHUK registered patient charity"},{"name":"Association of British Neurologists and Guarantors of the Brain for a 3-year Clinical Research Training Fellowship","id":[{"id":"https:\/\/ror.org\/00n9sg246","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/KO15184\/1"],"award-info":[{"award-number":["MR\/KO15184\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute of Health Research","doi-asserted-by":"crossref","award":["NIHR-CS-011-028"],"award-info":[{"award-number":["NIHR-CS-011-028"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000282","name":"Sir Jules Thorn Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are limited longitudinal data evaluating outcomes in idiopathic intracranial hypertension (IIH). We aimed to evaluate the long-term outcomes in a real-world cohort of patients with IIH and sought to establish the prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A longitudinal prospective cohort study was conducted over 9 years (2012\u20132021). Data included demographics and disease status. All consenting patients with IIH were recruited. Visual outcomes included visual acuity, Humphrey visual field and optical coherence tomography (OCT) imaging measurements. Headache frequency, severity, and impact were noted. We analysed the key variables impacting visual and headache outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort contained 490 patients with a confirmed IIH diagnosis. 98% were female with a mean body mass index (BMI) of 38\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Those with the highest OCT retinal nerve fibre layer had the worst visual outcomes. We noted a delayed decline, in the visual field and OCT ganglion cell layer after 12\u00a0months. In the medically managed cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009426), we found that disease duration and change in BMI had the greatest influence on visual outcomes. There was a high burden of headache, with a daily headache at presentation and prior migraine history influencing long-term headache prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is a delayed decline in visual outcomes in those with the most severe papilloedema. Disease duration and change in BMI were the key visual prognostic factors, therefore those with the more acute disease may require closer monitoring. Improving prognosis in IIH should focus on the potentially modifiable factor of weight management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-022-11402-6","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T01:02:29Z","timestamp":1665795749000},"page":"851-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2157","authenticated-orcid":false,"given":"Mark","family":"Thaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3639-7874","authenticated-orcid":false,"given":"Victoria","family":"Homer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8905-5734","authenticated-orcid":false,"given":"Andreas","family":"Yiangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Liczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6285-0703","authenticated-orcid":false,"given":"Anthony W.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-9696","authenticated-orcid":false,"given":"Jasvir","family":"Virdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Piccus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-5652","authenticated-orcid":false,"given":"Marianne","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-4437","authenticated-orcid":false,"given":"Susan P.","family":"Mollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-5132","authenticated-orcid":false,"given":"Alexandra J.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,15]]},"reference":[{"key":"11402_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145346","volume":"6","author":"CSJ Westgate","year":"2021","unstructured":"Westgate CSJ, Botfield HF, Alimajstorovic Z, Yiangou A, Walsh M, Smith G, Singhal R, Mitchell JL, Grech O, Markey KA, Hebenstreit D, Tennant DA, Tomlinson JW, Mollan SP, Ludwig C, Akerman I, Lavery GG, Sinclair AJ (2021) Systemic and adipocyte transcriptional and metabolic dysregulation in Idiopathic Intracranial Hypertension. JCI Insight 6:e145346","journal-title":"JCI Insight"},{"key":"11402_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/bmb\/ldaa034","volume":"136","author":"SP Mollan","year":"2020","unstructured":"Mollan SP, Grech O, Alimajstorovic Z, Wakerley BR, Sinclair AJ (2020) New horizons for idiopathic intracranial hypertension: advances and challenges. Br Med Bull 136:118\u2013126","journal-title":"Br Med Bull"},{"key":"11402_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001063","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Tahrani AA, Sinclair AJ (2021) The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight. Neurol Clin Pract. https:\/\/doi.org\/10.1212\/CPJ.0000000000001063","journal-title":"Neurol Clin Pract"},{"key":"11402_CR4","doi-asserted-by":"publisher","first-page":"fcab202","DOI":"10.1093\/braincomms\/fcab202","volume":"3","author":"O Grech","year":"2021","unstructured":"Grech O, Clouter A, Mitchell JL, Alimajstorovic Z, Ottridge RS, Yiangou A, Roque M, Tahrani AA, Nicholls M, Taylor AE, Shaheen F, Arlt W, Lavery GG, Shapiro K, Mollan SP, Sinclair AJ (2021) Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure. Brain Commun 3:fcab202","journal-title":"Brain Commun"},{"key":"11402_CR5","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/jnnp-2017-317440","volume":"89","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, Krishnan A, Chavda SV, Ramalingam S, Edwards J, Hemmings K, Williamson M, Burdon MA, Hassan-Smith G, Digre K, Liu GT, Jensen RH, Sinclair AJ (2018) Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry 89:1088\u20131100","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11402_CR6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1001\/jamaneurol.2019.1812","volume":"76","author":"NJ Adderley","year":"2019","unstructured":"Adderley NJ, Subramanian A, Nirantharakumar K, Yiangou A, Gokhale KM, Mollan SP, Sinclair AJ (2019) Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol 76:1088","journal-title":"JAMA Neurol"},{"key":"11402_CR7","first-page":"1","volume":"00","author":"M Thaller","year":"2022","unstructured":"Thaller M, Mytton J, Wakerley BR, Mollan SP, Sinclair AJ (2022) Idiopathic intracranial hypertension: evaluation of births and fertility through the hospital episode statistic dataset. BJOG 00:1\u20139","journal-title":"BJOG"},{"key":"11402_CR8","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00415-021-10700-9","volume":"269","author":"A Yiangou","year":"2022","unstructured":"Yiangou A, Mitchell JL, Nicholls M, Chong YJ, Vijay V, Wakerley BR, Lavery GG, Tahrani AA, Mollan SP, Sinclair AJ (2022) Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT). J Neurol 269:1945\u20131956","journal-title":"J Neurol"},{"key":"11402_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1212\/WNL.0000000000001896","volume":"85","author":"M Wall","year":"2015","unstructured":"Wall M, Falardeau J, Fletcher WA, Granadier RJ, Lam BL, Longmuir RA, Patel AD, Bruce BB, He H, McDermott MP (2015) Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Neurology 85:799\u2013805","journal-title":"Neurology"},{"key":"11402_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106463","volume":"205","author":"W Xu","year":"2021","unstructured":"Xu W, Prime Z, Papchenko T, Danesh-Meyer HV (2021) Long term outcomes of idiopathic intracranial hypertension: observational study and literature review. Clin Neurol Neurosurg 205:106463","journal-title":"Clin Neurol Neurosurg"},{"key":"11402_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41433-019-0359-5","volume":"33","author":"RJ Blanch","year":"2019","unstructured":"Blanch RJ, Vasseneix C, Liczkowski A, Yiangou A, Aojula A, Micieli JA, Mollan SP, Newman NJ, Biousse V, Bruce BB, Sinclair A (2019) Differing presenting features of idiopathic intracranial hypertension in the UK and US. Eye (Lond) 33:1014\u20131019","journal-title":"Eye (Lond)"},{"key":"11402_CR12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/head.14125","volume":"61","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Grech O, Sinclair AJ (2021) Headache attributed to idiopathic intracranial hypertension and persistent post-idiopathic intracranial hypertension headache: a narrative review. Headache 61:808\u2013816","journal-title":"Headache"},{"key":"11402_CR13","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00415-011-6273-9","volume":"259","author":"HM Yri","year":"2012","unstructured":"Yri HM, Wegener M, Sander B, Jensen R (2012) Idiopathic intracranial hypertension is not benign: a long-term outcome study. J Neurol 259:886\u2013894","journal-title":"J Neurol"},{"key":"11402_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s10194-021-01321-8","volume":"22","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Wakerley BR, Alimajstorovic Z, Mitchell J, Ottridge R, Yiangou A, Thaller M, Gupta A, Grech O, Lavery G, Brock K, Sinclair AJ (2021) Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension. J Headache Pain 22:118","journal-title":"J Headache Pain"},{"key":"11402_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2701","volume":"341","author":"AJ Sinclair","year":"2010","unstructured":"Sinclair AJ, Burdon MA, Nightingale PG, Ball AK, Good P, Matthews TD, Jacks A, Lawden M, Clarke CE, Stewart PM, Walker EA, Tomlinson JW, Rauz S (2010) Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 341:c2701","journal-title":"BMJ"},{"key":"11402_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamaneurol.2021.0659","volume":"78","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Mitchell JL, Ottridge RS, Aguiar M, Yiangou A, Alimajstorovic Z, Cartwright DM, Grech O, Lavery GG, Westgate CSJ, Vijay V, Scotton W, Wakerley BR, Matthews TD, Ansons A, Hickman SJ, Benzimra J, Rick C, Singhal R, Tahrani AA, Brock K, Frew E, Sinclair AJ (2021) Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurol 78:678\u2013686","journal-title":"JAMA Neurol"},{"key":"11402_CR17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.soard.2021.03.020","volume":"17","author":"L Elliot","year":"2021","unstructured":"Elliot L, Frew E, Mollan SP, Mitchell JL, Yiangou A, Alimajstorovic Z, Ottridge RS, Wakerley BR, Thaller M, Grech O, Singhal R, Tahrani AA, Harrison M, Sinclair AJ, Aguiar M (2021) Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension: evidence from a single-payer healthcare system. Surg Obes Relat Dis 17:1310\u20131316","journal-title":"Surg Obes Relat Dis"},{"key":"11402_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/0972-2327.78044","volume":"14","author":"NN Baheti","year":"2011","unstructured":"Baheti NN, Nair M, Thomas SV (2011) Long-term visual outcome in idiopathic intracranial hypertension. Ann Indian Acad Neurol 14:19\u201322","journal-title":"Ann Indian Acad Neurol"},{"key":"11402_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2020-325519","volume":"92","author":"M Thaller","year":"2021","unstructured":"Thaller M, Tsermoulas G, Sun R, Mollan SP, Sinclair AJ (2021) Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 92:795\u2013797","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11402_CR20","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.2014.3312","volume":"311","author":"M Wall","year":"2014","unstructured":"Nordic Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ (2014) Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 311:1641\u20131651","journal-title":"JAMA"},{"key":"11402_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/life11050417","volume":"11","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Mytton J, Tsermoulas G, Sinclair AJ (2021) Idiopathic intracranial hypertension: evaluation of admissions and emergency readmissions through the hospital episode statistic dataset between 2002\u20132020. Life 11:417","journal-title":"Life"},{"key":"11402_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29669","volume":"3","author":"AG Hamedani","year":"2020","unstructured":"Hamedani AG, Thibault DP, Revere KE, Lee JYK, Grady MS, Willis AW, Liu GT (2020) Trends in the surgical treatment of pseudotumor Cerebri syndrome in the United States. JAMA Netw Open 3:e2029669","journal-title":"JAMA Netw Open"},{"key":"11402_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/aos.13664","volume":"96","author":"CF Hatem","year":"2018","unstructured":"Hatem CF, Yri HM, Sorensen AL, Wegener M, Jensen RH, Hamann S (2018) Long-term visual outcome in a Danish population of patients with idiopathic intracranial hypertension. Acta Ophthalmol 96:719\u2013723","journal-title":"Acta Ophthalmol"},{"key":"11402_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/tjo.tjo_44_20","volume":"11","author":"JA Micieli","year":"2021","unstructured":"Micieli JA, Gorham JP, Bruce BB, Newman NJ, Biousse V, Peragallo JH (2021) Clinical and demographic differences between idiopathic intracranial hypertension patients with mild and severe papilledema. Taiwan J Ophthalmol 11:53\u201356","journal-title":"Taiwan J Ophthalmol"},{"key":"11402_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/01658107.2021.1984540","volume":"46","author":"R Behbehani","year":"2022","unstructured":"Behbehani R, Ali A, Al-Moosa A (2022) Course and predictors of visual outcome of idiopathic intracranial hypertension. Neuroophthalmology 46:80\u201384","journal-title":"Neuroophthalmology"},{"key":"11402_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000446","author":"SM Hermes","year":"2022","unstructured":"Hermes SM, Bharadwaj M, Miller NR, Waslo C, Husain FA, Wolfe BM, Tanne E (2022) Long-term outcomes of bariatric surgery in idiopathic intracranial hypertension patients. Neurologist. https:\/\/doi.org\/10.1097\/NRL.0000000000000446","journal-title":"Neurologist"},{"key":"11402_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/EB.S193027","volume":"12","author":"SP Gurney","year":"2020","unstructured":"Gurney SP, Ramalingam S, Thomas A, Sinclair AJ, Mollan SP (2020) Exploring the current management idiopathic intracranial hypertension, and understanding the role of dural venous sinus stenting. Eye Brain 12:1\u201313","journal-title":"Eye Brain"},{"key":"11402_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120271","volume":"437","author":"L Donaldson","year":"2022","unstructured":"Donaldson L, Jhaveri A, Micieli J, Margolin E (2022) Idiopathic intracranial hypertension in atypical demographics. J Neurol Sci 437:120271","journal-title":"J Neurol Sci"},{"key":"11402_CR29","doi-asserted-by":"publisher","first-page":"fcaa108","DOI":"10.1093\/braincomms\/fcz050","volume":"2","author":"K Markey","year":"2020","unstructured":"Markey K, Mitchell J, Botfield H, Ottridge RS, Matthews T, Krishnan A, Woolley R, Westgate C, Yiangou A, Alimajstorovic Z, Shah P, Rick C, Ives N, Taylor AE, Gilligan LC, Jenkinson C, Arlt W, Scotton W, Fairclough RJ, Singhal R, Stewart PM, Tomlinson JW, Lavery GG, Mollan SP, Sinclair AJ (2020) 11\u03b2-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Commun 2:fcaa108","journal-title":"Brain Commun"},{"key":"11402_CR30","doi-asserted-by":"crossref","unstructured":"Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, Greig NH, Li Y, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ (2022) The effect of exenatide on intracranial pressure in Idiopathic Intracranial Hypertension, IIH pressure: a randomised clinical trial. medRxiv:2022.2005.2024.22275518","DOI":"10.1101\/2022.05.24.22275518"},{"key":"11402_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","volume":"81","author":"DI Friedman","year":"2013","unstructured":"Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81:1159\u20131165","journal-title":"Neurology"},{"key":"11402_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jnnp.45.1.13","volume":"45","author":"L Frisen","year":"1982","unstructured":"Frisen L (1982) Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry 45:13\u201318","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11402_CR33","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/jamaophthalmol.2020.4242","volume":"138","author":"V Vijay","year":"2020","unstructured":"Vijay V, Mollan SP, Mitchell JL, Bilton E, Alimajstorovic Z, Markey KA, Fong A, Walker JK, Lyons HS, Yiangou A, Tsermoulas G, Brock K, Sinclair AJ (2020) Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension. JAMA Ophthalmol 138:1264\u20131271","journal-title":"JAMA Ophthalmol"},{"key":"11402_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12886-017-0652-7","volume":"17","author":"A Aojula","year":"2018","unstructured":"Aojula A, Mollan SP, Horsburgh J, Yiangou A, Markey KA, Mitchell JL, Scotton WJ, Keane PA, Sinclair AJ (2018) Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension. BMC Ophthalmol 17:257","journal-title":"BMC Ophthalmol"},{"key":"11402_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committe of the International Headache Society","year":"2013","unstructured":"Headache Classification Committe of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629\u2013808","journal-title":"Cephalalgia"},{"key":"11402_CR36","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Garber WH, Batenhorst A, Cady R, Dahl\u00f6f CGH, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6\u2122. Qual Life Res 12:963\u2013974","journal-title":"Qual Life Res"},{"key":"11402_CR37","unstructured":"R Core Team (2018) R: a language and environment for statistical computing. In:R Foundation for Statistical Computing, Vienna, Austria"},{"key":"11402_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"DMM Bates","year":"2015","unstructured":"Bates DMM, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67:1\u201348","journal-title":"J Stat Softw"},{"key":"11402_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/archophthalmol.2010.94","volume":"128","author":"CJ Scott","year":"2010","unstructured":"Scott CJ (2010) Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch Ophthalmol 128:705","journal-title":"Arch Ophthalmol"},{"key":"11402_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00415-010-5750-x","volume":"258","author":"M Skau","year":"2011","unstructured":"Skau M, Sander B, Milea D, Jensen R (2011) Disease activity in idiopathic intracranial hypertension: a 3-month follow-up study. J Neurol 258:277\u2013283","journal-title":"J Neurol"},{"key":"11402_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sjopt.2014.09.016","volume":"29","author":"G Rebolleda","year":"2015","unstructured":"Rebolleda G, Diez-Alvarez L, Casado A, S\u00e1nchez-S\u00e1nchez C, de Dompablo E, Gonz\u00e1lez-L\u00f3pez JJ, Mu\u00f1oz-Negrete FJ (2015) OCT: New perspectives in neuro-ophthalmology. Saudi J Ophthalmol 29:9\u201325","journal-title":"Saudi J Ophthalmol"},{"key":"11402_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/practneurol-2020-002824","volume":"21","author":"C Fraser","year":"2021","unstructured":"Fraser C, Lueck CJ (2021) Optical coherence tomography: a window to the brain? Pract Neurol 21:313\u2013321","journal-title":"Pract Neurol"},{"key":"11402_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/01658107.2018.1476558","volume":"43","author":"G Athappilly","year":"2019","unstructured":"Athappilly G, Garc\u00eda-Basterra I, Machado-Miller F, Hedges TR, Mendoza-Santiesteban C, Vuong L (2019) Ganglion cell complex analysis as a potential indicator of early neuronal loss in idiopathic intracranial hypertension. Neuro-Ophthalmology 43:10\u201317","journal-title":"Neuro-Ophthalmology"},{"key":"11402_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/eye.2013.301","volume":"28","author":"MLR Monteiro","year":"2014","unstructured":"Monteiro MLR, Afonso CL (2014) Macular thickness measurements with frequency domain-OCT for quantification of axonal loss in chronic papilledema from pseudotumor cerebri syndrome. Eye 28:390\u2013398","journal-title":"Eye"},{"key":"11402_CR45","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/jnnp-2014-309704","volume":"86","author":"F Costello","year":"2015","unstructured":"Costello F, Pan YI, Yeh EA, Hodge W, Burton JM, Kardon R (2015) The temporal evolution of structural and functional measures after acute optic neuritis. J Neurol Neurosurg Psychiatry 86:1369\u20131373","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11402_CR46","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/FOC-07\/11\/E5","volume":"23","author":"CM Schirmer","year":"2007","unstructured":"Schirmer CM, Hedges TR (2007) Mechanisms of visual loss in papilledema. Neurosurgical Focus FOC 23:E5","journal-title":"Neurosurgical Focus FOC"},{"key":"11402_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026573","volume":"9","author":"S Mollan","year":"2019","unstructured":"Mollan S, Hemmings K, Herd CP, Denton A, Williamson S, Sinclair AJ (2019) What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open 9:e026573","journal-title":"BMJ Open"},{"key":"11402_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14737175.2021.1931127","volume":"21","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Sinclair AJ (2021) Outcomes measures in idiopathic intracranial hypertension. Expert Rev Neurother 21:687\u2013700","journal-title":"Expert Rev Neurother"},{"key":"11402_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0875-x","author":"N Vandenbussche","year":"2018","unstructured":"Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, Toom K, Vandervorst F, Quintana S, Paemeleire K, Katsarava Z (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-018-0875-x","journal-title":"J Headache Pain"},{"key":"11402_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/head.14026","volume":"61","author":"A Yiangou","year":"2021","unstructured":"Yiangou A, Mitchell JL, Fisher C, Edwards J, Vijay V, Alimajstorovic Z, Grech O, Lavery GG, Mollan SP, Sinclair AJ (2021) Erenumab for headaches in idiopathic intracranial hypertension: a prospective open-label evaluation. Headache 61:157\u2013169","journal-title":"Headache"},{"key":"11402_CR51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s10194-020-01182-7","volume":"21","author":"A Yiangou","year":"2020","unstructured":"Yiangou A, Mitchell JL, Vijay V, Grech O, Bilton E, Lavery GG, Fisher C, Edwards J, Mollan SP, Sinclair AJ (2020) Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. J Headache Pain 21:116","journal-title":"J Headache Pain"},{"key":"11402_CR52","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41433-021-01421-4","volume":"35","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Virdee JS, Bilton EJ, Thaller M, Krishan A, Sinclair AJ (2021) Headache for ophthalmologists: current advances in headache understanding and management. Eye (Lond) 35:1574\u20131586","journal-title":"Eye (Lond)"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11402-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11402-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11402-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T05:03:23Z","timestamp":1675227803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11402-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["11402"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11402-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,15]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MT, VH, YH, AL, AF, JV, RP, MR report no conflicts. AY reports speaker fees for an educational talk from Teva, UK. SPM reports consultancy fees (Invex Therapeutics; Neurodiem); advisory board fees (Invex therapeutics; Janssen) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; and Santhera). AJS reports personal fees from Invex therapeutics during the conduct of the study as well as share option and shareholdings, speaker fees (Novartis; Allergan; Teva UK) and consulting fees (Allergan; Chiesi; Novartis; Lundbeck).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study sponsor and funders had no role in the study design, interpretation of the data, data collection, or drafting of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The study was ethically approved by National Health Service National Research Ethics Committee (14\/LO\/1208), IIH:LIFE study. The human study has been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}